Advisor Group Holdings, Inc. Annovis Bio, Inc. Transaction History

Advisor Group Holdings, Inc.

$42.2 Billion
Q3 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,200 shares of ANVS stock, worth $8,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,200

Previous 1,275 5.88%

Holding current value

$8,484

Previous $7,000 28.57%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$5.27 - $15.46 $395 - $1,159	-75 Reduced 5.88%	1,200 $9,000
Q2 2024 Aug 13, 2024	BUY	$4.82 - $18.01 $361 - $1,350	75 Added 6.25%	1,275 $7,000
Q3 2023 Nov 13, 2023	SELL	$9.37 - $14.12 $8,957 - $13,498	-956 Reduced 44.34%	1,200 $11,000
Q1 2023 May 12, 2023	SELL	$12.33 - $22.1 $14,919 - $26,741	-1,210 Reduced 35.95%	2,156 $33,000
Q4 2022 Feb 10, 2023	BUY	$10.99 - $13.8 $945 - $1,186	86 Added 2.62%	3,366 $45,000
Q3 2022 Nov 14, 2022	BUY	$10.26 - $21.81 $12,414 - $26,390	1,210 Added 58.45%	3,280 $45,000
Q2 2022 Aug 10, 2022	SELL	$8.61 - $13.87 $6,888 - $11,096	-800 Reduced 27.87%	2,070 $25,000
Q1 2022 May 04, 2022	SELL	$11.84 - $19.78 $96,282 - $160,850	-8,132 Reduced 73.91%	2,870 $38,000
Q3 2021 Nov 05, 2021	BUY	$30.95 - $120.97 $286,597 - $1.12 Million	9,260 Added 531.57%	11,002 $349,000
Q2 2021 Aug 02, 2021	SELL	$21.55 - $96.1 $52,969 - $236,213	-2,458 Reduced 58.52%	1,742 $149,000
Q1 2021 May 13, 2021	SELL	$8.15 - $38.44 $26,047 - $122,854	-3,196 Reduced 43.21%	4,200 $117,000
Q4 2020 Feb 10, 2021	SELL	$4.36 - $7.54 $1,909 - $3,302	-438 Reduced 5.59%	7,396 $56,000
Q3 2020 Nov 12, 2020	BUY	$3.84 - $6.78 $28,450 - $50,233	7,409 Added 1743.29%	7,834 $38,000
Q1 2020 May 18, 2020	BUY	$2.66 - $9.59 $1,130 - $4,075	425 New	425 $1,000

Others Institutions Holding ANVS

# of Institutions

Shares Held

1.17M

Call Options Held

229K

Put Options Held

934K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $57.7M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Annovis Bio, Inc. Transaction History